Dr Yeadon is a co-founder of Ziarco and CEO. He is an Allergy & Respiratory therapeutic area expert, developed out of deep knowledge of biology & therapeutics, and is an innovative drug discoverer with over 25 years of experience in drug discovery and development.
Dr Yeadon has published over 40 original research articles and since 2011 has consulted to more than 20 biotechnology companies.
Prior to consulting as an independent, he was Vice President and Chief Scientific Officer of the A&R Research Unit of Pfizer. At Pfizer, Dr Yeadon was responsible for target selection and the progress into humans of new molecules, leading teams of up to 200 staff across all disciplines.
Before that, Dr Yeadon worked at the Wellcome Research Labs with Salvador Moncada with a research focus on airway hyper-responsiveness and effects of pollutants including ozone and working in drug discovery of 5-LO, COX, NO and lung inflammation.
He attended the University of Surrey in Guildford, U.K, where (1988), he received his PhD with thesis work in the respiratory field, and a BSc, First Class, with Joint Honours, in Biochemistry and Toxicology.
-Senior Principal Scientist, Wellcome Research (1988-1995)
-Chief Scientific Officer, Allergy & Respiratory Research, Pfizer R&D (1995-2011)
-VP Allergy & Respiratory Head, Research, Pfizer Global R&D (2005-2008)
-CSO & VP ALlergy & Respiratory Research Head, Pfizer Global R&D (2006-2011)
-Consultant (Scientific Advisory Board), Pulmatrix (2011-2016)
-Consultant, Apellis Pharmacuticals (2011-2016)
-Co-Founder, Ziarco (2011-2017)